Cart
sales@molnova.com
Sulfacetamide sodium salt hydrate
CAS No. 6209-17-2
Sulfacetamide sodium salt hydrate( —— )
Catalog No. M15350 CAS No. 6209-17-2
Sulfacetamide sodium monohydrate is a sulfonamide antibiotic, has been investigated for use in the treatment of pityriasis versicolor and rosacea.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 27 | In Stock |
|
| 100MG | 47 | In Stock |
|
| 200MG | 77 | In Stock |
|
| 500MG | 128 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSulfacetamide sodium salt hydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionSulfacetamide sodium monohydrate is a sulfonamide antibiotic, has been investigated for use in the treatment of pityriasis versicolor and rosacea.
-
DescriptionSulfacetamide sodium monohydrate is a sulfonamide antibiotic, has been investigated for use in the treatment of pityriasis versicolor and rosacea.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorDHPS
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number6209-17-2
-
Formula Weight254.2
-
Molecular FormulaC8H9N2NaO3S·H2O
-
Purity>98% (HPLC)
-
SolubilitySoluble in Water
-
SMILESO.[Na].CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ZPCK
ZPCK is a potent, pan autophagy inhibitor, inhibits the cargo degradation inside the vacuole and alters the process of autophagy in mammalian cells.
-
Glaucocalyxin B
Glaucocalyxin B is a diterpenoid isolated from Rabdosia japonica with anticancer and antitumor activity. It decreases the growth of HL-60 cells (IC50: 5.86 μM).
-
LYN-1604 2HCl 221675...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604, to be the best candidate for a ULK1 agonist.?LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.
